Novel advances in juvenile idiopathic arthritis associated uveitis
JIA-U remains a lifelong, vision-threatening condition despite advances in screening, diagnostics, and treatment. Integration of biomarker-based risk stratification, advanced imaging, and precision pharmacology holds promise for earlier detection and personalised care. Addressing psychosocial impacts through family-centred, multidisciplinary frameworks is essential. Future priorities include validating predictive biomarkers, refining tapering protocols, and ensuring equitable access to novel diagnostics and therapeutics to optimise lifelong outcomes.
Authors
- Ameenat Lola Solebo (ORCID: https://orcid.org/0000-0002-8933-5864)
- Nisha R. Acharya
- Anamika Patel
Institutions
- Moorfields Eye Hospital NHS Foundation Trust (GB)
- University of California, San Francisco (US)
- Great Ormond Street Hospital (GB)
- San Francisco Foundation (US)
- Institute of Child Health (GR)
- UCL Biomedical Research Centre (GB)
- Moorfields Eye Hospital (GB)
- University College London (GB)
Publication Details
- Journal
- Arthritis Research & Therapy
- Published
- 2026-02-27
- DOI
- https://doi.org/10.1186/s13075-026-03758-1
- Primary Topic
- Ocular Diseases and Behçet’s Syndrome
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wellcome Trust
- National Institute for Health and Care Research
- Moorfields Eye Hospital NHS Foundation Trust